v3.26.1
Segment Information - Schedule of Segment Reporting Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]        
Total revenue from reportable segments $ 430,933 $ 408,160 $ 1,296,846 $ 1,181,492
Cost of commissions and other services revenue (83,268) (79,412) (255,403) (246,283)
Cost of goods sold—pharmacy revenue (171,289) (162,304) (569,262) (448,029)
Marketing expense (92,481) (92,733) (259,456) (254,222)
Technical development (9,777) (9,967) (29,283) (29,086)
Selling, general, and administrative (38,188) (41,685) (112,948) (122,850)
Adjusted Segment EBITDA 70,004 58,510 170,629 187,230
All Other Adjusted EBITDA 1,376 3,549 5,366 9,645
Corporate (26,790) (24,336) (78,752) (73,316)
Share-based compensation expense (3,678) (4,960) (11,480) (13,505)
Transaction costs (631) (5,813) (1,478) (13,358)
Depreciation and amortization (4,385) (4,925) (13,007) (15,584)
Loss on disposal of property, equipment, and software, net   (3)   (160)
Impairment of equity-method investment     (1,000) 0
LOSS ON EXTINGUISHMENT OF DEBT (8,659) 0 (8,659) 0
Change in fair value of warrants 27,489 32,986 61,821 25,344
Interest expense, net (10,602) (20,407) (34,023) (67,160)
INCOME BEFORE INCOME TAX EXPENSE 44,124 34,601 89,417 39,136
Unallocated corporate expenses 17,400 16,600 52,600 49,500
Professional services 5,400 3,800 14,600 12,600
Facilities 1,200 1,400 4,000 4,200
Severance expenses     1,000 600
Financing transaction costs 600 5,800 500 12,800
Operating Segments        
Segment Reporting Information [Line Items]        
Total revenue from reportable segments 430,172 404,853 1,292,983 1,171,600
Cost of commissions and other services revenue
Cost of goods sold—pharmacy revenue
Marketing expense
Technical development
Selling, general, and administrative
Operating Segments | Senior        
Segment Reporting Information [Line Items]        
Total revenue from reportable segments 182,890 169,442 503,426 517,930
Cost of commissions and other services revenue (54,596) (53,374) (170,884) (169,543)
Cost of goods sold—pharmacy revenue 0 0 0 0
Marketing expense (69,060) (69,808) (190,746) (192,583)
Technical development 0 0 0 0
Selling, general, and administrative (592) (559) (1,739) (1,855)
Adjusted Segment EBITDA 58,642 45,701 140,057 153,949
Operating Segments | Healthcare Services        
Segment Reporting Information [Line Items]        
Total revenue from reportable segments 199,386 189,569 651,391 528,677
Cost of commissions and other services revenue (6,976) (5,816) (21,635) (19,627)
Cost of goods sold—pharmacy revenue (169,814) (161,026) (564,995) (444,401)
Marketing expense (1,686) (1,939) (6,309) (6,088)
Technical development (318) (491) (1,068) (1,691)
Selling, general, and administrative (15,314) (13,852) (44,048) (43,336)
Adjusted Segment EBITDA 5,278 6,445 13,336 13,534
Operating Segments | Life        
Segment Reporting Information [Line Items]        
Total revenue from reportable segments 47,896 45,842 138,166 124,993
Cost of commissions and other services revenue (18,465) (17,415) (53,848) (47,028)
Cost of goods sold—pharmacy revenue 0 0 0 0
Marketing expense (23,131) (21,789) (66,267) (57,456)
Technical development 0 0 0 0
Selling, general, and administrative (216) (274) (815) (762)
Adjusted Segment EBITDA $ 6,084 $ 6,364 $ 17,236 $ 19,747